Gene Expression Profiling of CD23+ T(14;18)-negative follicular lymphoma demonstrates activation of the IL4/JAK/STAT6 pathway and a role in its pathogenesis
- Categories
- Abstracts
- Topics:
- Lymphoma
- PIP
- STAT6 pathway
Pritchett, J. C., et al., High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL), Leukemia 2021. https://doi.org/10.1038/s41375-021-01321-2
Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021
Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.
Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.
Gaudio, E., et al. Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identificaton of Potential Biomarkers for Its Activity. Blood Journal 2020 NOV 6. 136 (S1);17
Tiemann, A., et al. Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma. Poster and Abstract 263 presentedDeutsche Gesellschaft Fur Hamatologie Und Medizinische Onkologie. at Virtual Annual Meeting 2020 OCT 9 - 11.
Armand, P., et. al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. 2020 AUG 31. https://doi.org/10.1182/blood.2019004753
Menter, T., et al. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. British Journal of Haematology; 2020 Jun. doi: 10.1111/bjh.16876
Zhou H., et al. Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up. Blood Cancer Journal (2020)10:49
Page last updated May 22, 2023